{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:39:10Z","timestamp":1790404750682,"version":"4.1.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01417","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T05:45:01Z","timestamp":1576561501000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Precision Medicine in Lymphoma by Innovative Instrumental Platforms"],"prefix":"10.3389","volume":"9","author":[{"given":"Antonello","family":"Di Paolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Arrigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Luci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrclinonc.2012.156","article-title":"From drug discovery to biomarker-driven clinical trials in lymphoma","volume":"9","author":"Younes","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-981-10-5187-6_10","article-title":"Pharmacogenetics and personalized medicine","volume-title":"Drug Design: Principles and Applications","author":"Di Paolo","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR-ABL story: bench to bedside and back","volume":"22","author":"Wong","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bbcan.2012.07.001","article-title":"A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells","volume":"1826","author":"Icard","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B5","doi-asserted-by":"publisher","first-page":"50949","DOI":"10.18632\/oncotarget.16435","article-title":"mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish lymphoma oncology group","volume":"8","author":"Provencio","year":"2017","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2013-05-502211","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/PAI.0000000000000020","article-title":"Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction","volume":"22","author":"Jim\u00e9nez","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","article-title":"Highly sensitive MYD88l265p mutation detection by droplet digital polymerase chain reaction in Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Drandi","year":"2018","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fonc.2018.00382","article-title":"Detection of the MYD88p.L265P mutation in the CSF of a patient with secondary central nervous system lymphoma","volume":"8","author":"Zorofchian","year":"2018","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jamaophthalmol.2018.2887","article-title":"Potential diagnosis of vitreoretinal lymphoma by detection of MYD88 mutation in aqueous humor with ultrasensitive droplet digital polymerase chain reaction","volume":"136","author":"Hiemcke-Jiwa","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/hon.2489","article-title":"The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p. (L265P) detection in cerebrospinal fluid","volume":"36","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-15-2305","article-title":"Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study","volume":"22","author":"Dubois","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1373\/clinchem.2016.262824","article-title":"RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia","volume":"63","author":"Alikian","year":"2017","journal-title":"Clin Chem"},{"key":"B15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00428-017-2137-8","article-title":"Liquid biopsy: unlocking the potentials of cell-free DNA","volume":"471","author":"Chu","year":"2017","journal-title":"Virchows Arch"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14737159.2018.1400384","article-title":"Droplet-based digital PCR and next generation sequencing for monitoring circulating tumour DNA: a cancer diagnostic perspective","volume":"18","author":"Postel","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"B17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/23808993.2017.1347482","article-title":"Applications of digital PCR in precision medicine","volume":"2","author":"Wong","year":"2017","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s00277-018-3451-1","article-title":"A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs","volume":"97","author":"Link-Lenczowska","year":"2018","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"E91","DOI":"10.3390\/jcm6100091","article-title":"Comparison of minimal residual disease detection by multiparameter flow cytometry, ASO-qPCR, droplet digital PCR, and deep sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation","volume":"6","author":"Takamatsu","year":"2017","journal-title":"J Clin Med"},{"key":"B20","first-page":"1","year":"2015","journal-title":"Ibrutinib - Technical Note"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstr\u00f6m macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4 S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.05.010","article-title":"Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: review of literature and future opportunities","volume":"127","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","article-title":"CSF, blood-brain barrier, and brain drug delivery","volume":"13","author":"Pardridge","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1517\/17425255.2015.1053460","article-title":"Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs","volume":"11","author":"Di Paolo","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/14737159.2017.1268533","article-title":"NanoString, a novel digital color-coded barcode technology: current and future applications in molecular diagnostics","volume":"17","author":"Tsang","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e6986","DOI":"10.1371\/journal.pone.0006986","article-title":"A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms","volume":"4","author":"Martin-Subero","year":"2009","journal-title":"PLoS ONE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/tpj.2011.38","article-title":"Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations","volume":"13","author":"Wheeler","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12881-014-0113-6","article-title":"A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival","volume":"15","author":"Baecklund","year":"2014","journal-title":"BMC Med Genet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00320-1","article-title":"Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility","volume":"8","author":"Sud","year":"2017","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2018-06-855296","article-title":"Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma","volume":"132","author":"Sud","year":"2018","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0193098","DOI":"10.1371\/journal.pone.0193098","article-title":"Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach","volume":"13","author":"de Jong","year":"2018","journal-title":"PLoS ONE"},{"key":"B33","doi-asserted-by":"publisher","first-page":"111386","DOI":"10.18632\/oncotarget.22799","article-title":"Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets","volume":"8","author":"Mata","year":"2017","journal-title":"Oncotarget"},{"key":"B34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.gene.2017.11.022","article-title":"Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions","volume":"642","author":"Meng","year":"2018","journal-title":"Gene"},{"key":"B35","first-page":"3905","article-title":"Glutathione-s-transferases and chemotherapy resistance of Hodgkin's lymphoma cell lines","volume":"36","author":"Bernig","year":"2016","journal-title":"Anticancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pharmthera.2016.02.008","article-title":"Cancer stem cells and chemoresistance: the smartest survives the raid","volume":"160","author":"Zhao","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.18632\/oncotarget.13690","article-title":"FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma","volume":"8","author":"Ryu","year":"2017","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e79602","DOI":"10.1371\/journal.pone.0079602","article-title":"Identification of highly methylated genes across various types of B-cell non-Hodgkin lymphoma","volume":"8","author":"Bethge","year":"2013","journal-title":"PLoS ONE"},{"key":"B42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/10245332.2017.1299417","article-title":"ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia","volume":"22","author":"Abdullah","year":"2017","journal-title":"Hematology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.18632\/oncotarget.6198","article-title":"EZH2 in normal hematopoiesis and hematological malignancies","volume":"7","author":"Herviou","year":"2016","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.humpath.2018.08.025","article-title":"Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK\/T-cell lymphoma, nasal type is associated with disease progression and prognosis","volume":"83","author":"Liu","year":"2019","journal-title":"Hum Pathol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/path.5108","article-title":"Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma","volume":"246","author":"Liu","year":"2018","journal-title":"J Pathol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-018-0684-3","article-title":"Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China cancer immunotherapy workshop in Beijing","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.3389\/fimmu.2018.02737","article-title":"CTLA-4 and PD-1 control of T-cell motility and migration: implications for tumour immunotherapy","volume":"9","author":"Brunner-Weinzierl","year":"2018","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.02.027","article-title":"The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: the future is now","volume":"113","author":"Ju\u00e1rez-Salcedo","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00277-017-3176-6","article-title":"PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas","volume":"97","author":"Wang","year":"2018","journal-title":"Ann Hematol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1188246","DOI":"10.1080\/2162402X.2016.1188246","article-title":"Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas","volume":"5","author":"Tosolini","year":"2016","journal-title":"Oncoimmunology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ebiom.2018.06.010","article-title":"Immune characteristics of Chinese diffuse large B-cell lymphoma patients: implications for cancer immunotherapies","volume":"33","author":"Xu","year":"2018","journal-title":"EBioMedicine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/sctm.17-0175","article-title":"Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment","volume":"7","author":"Arrigoni","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2217\/pgs.14.106","article-title":"Pharmacogenetics of childhood acute lymphoblastic leukemia","volume":"15","author":"Lopez-Lopez","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1080\/17425255.2016.1215423","article-title":"ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview","volume":"12","author":"Arrigoni","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1093\/hmg\/dds302","article-title":"PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity","volume":"21","author":"Stocco","year":"2012","journal-title":"Hum Mol Genet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/blood-2015-02-628800","article-title":"Genome-wide analysis links NFATC2 with asparaginase hypersensitivity","volume":"126","author":"Fernandez","year":"2015","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/FPC.0000000000000293","article-title":"Genetics of pleiotropic effects of dexamethasone","volume":"27","author":"Ramsey","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3324\/haematol.2017.168211","article-title":"HLA-DRB1*07:01-HLA-DQA1*02:01-HLADQB1* 02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia","volume":"102","author":"Kutszegi","year":"2017","journal-title":"Haematologica"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e1002822","DOI":"10.1371\/journal.pcbi.1002822","article-title":"Chapter 11: genome-wide association studies","volume":"8","author":"Bush","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ding","year":"2008","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"E498","DOI":"10.1073\/pnas.1715118115","article-title":"Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma","volume":"115","author":"Lu","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.critrevonc.2018.04.002","article-title":"Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia","volume":"126","author":"Wu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40246-018-0157-3","article-title":"Integrating rare genetic variants into pharmacogenetic drug response predictions","volume":"12","author":"Ingelman-Sundberg","year":"2018","journal-title":"Hum Genomics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/leu.2009.114","article-title":"Array-based DNA methylation profiling in follicular lymphoma","volume":"23","author":"O'Riain","year":"2009","journal-title":"Leukemia"},{"key":"B66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.canlet.2012.10.040","article-title":"Analyzing the cancer methylome through targeted bisulfite sequencing","volume":"340","author":"Lee","year":"2013","journal-title":"Cancer Lett"},{"key":"B67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ymeth.2014.10.032","article-title":"Combining MeDIP-seq and MRE-seq to investigate genome-wide CpG methylation","volume":"72","author":"Li","year":"2015","journal-title":"Methods"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2015.11.003","article-title":"The impact of next-generation sequencing on the DNA methylation-based translational cancer research","volume":"169","author":"Soto","year":"2016","journal-title":"Transl Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"E429","DOI":"10.3390\/genes9090429","article-title":"Profiling DNA methylation based on next-generation sequencing approaches: new insights and clinical applications","volume":"9","author":"Barros-Silva","year":"2018","journal-title":"Genes"},{"key":"B70","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.leukres.2013.08.020","article-title":"Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)","volume":"37","author":"Mazan-Mamczarz","year":"2013","journal-title":"Leuk Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/epi-2018-0123","article-title":"Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance","volume":"11","author":"Feng","year":"2018","journal-title":"Epigenomics."},{"key":"B73","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3892\/ol.2015.3866","article-title":"Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients","volume":"11","author":"Yuan","year":"2016","journal-title":"Oncol Lett"},{"key":"B74","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br J Haematol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40262-015-0324-9","article-title":"Impact of new genomic technologies on understanding adverse drug reactions","volume":"55","author":"Maggo","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"B76","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/clpt.2010.94","article-title":"Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity","volume":"88","author":"Chen","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e0140136","DOI":"10.1371\/journal.pone.0140136","article-title":"Subgroups of paediatric acute lymphoblastic leukaemia might differ significantly in genetic predisposition to asparaginase hypersensitivity","volume":"10","author":"Kutszegi","year":"2015","journal-title":"PLoS ONE"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.3109\/10428194.2015.1020802","article-title":"Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia","volume":"56","author":"Raji\u0107","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1182\/blood-2014-03-563742","article-title":"HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies","volume":"124","author":"Fernandez","year":"2014","journal-title":"Blood"},{"key":"B80","year":"2012","journal-title":"Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products"},{"key":"B81","first-page":"1","year":"2018","journal-title":"Guideline on Good Pharmacogenomic Practice"},{"key":"B82","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3978\/j.issn.2218-676X.2014.05.04","article-title":"Biomarker adaptive designs in clinical trials","volume":"3","author":"Chen","year":"2014","journal-title":"Transl Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-07-4531","article-title":"The use of genomics in clinical trial design","volume":"14","author":"Simon","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/10543400902802458","article-title":"Clinical trial designs for predictive biomarker validation: one size does not fit all","volume":"19","author":"Mandrekar","year":"2009","journal-title":"J Biopharm Stat"},{"key":"B85","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jnci\/djp477","article-title":"Randomized clinical trials with biomarkers: design issues","volume":"102","author":"Freidlin","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"B86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2018.12.003","article-title":"New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology","volume":"73","author":"Janiaud","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B87","doi-asserted-by":"publisher","first-page":"39538","DOI":"10.18632\/oncotarget.5946","article-title":"Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses","volume":"6","author":"Ocana","year":"2015","journal-title":"Oncotarget"},{"key":"B88","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.critrevonc.2018.11.008","article-title":"Complexity of Genome Sequencing and Reporting: next generation sequencing (NGS) technologies and implementation of precision medicine in real life","volume":"133","author":"Morganti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1089\/cmb.2012.0283","article-title":"Calculating sample size estimates for RNA sequencing data","volume":"20","author":"Hart","year":"2013","journal-title":"J Comput Biol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing\u2013based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagnostics"},{"key":"B91","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1634\/theoncologist.2015-0279","article-title":"Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients","volume":"21","author":"Ciardiello","year":"2016","journal-title":"Oncologist"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2476-2024.1000e102","article-title":"Should the next generation sequencing be used as a diagnostic test?","volume":"1","author":"Furmaga","year":"2016","journal-title":"Diagnostic Pathol Open Access"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1182\/blood.V130.Suppl_1.3451.3451","article-title":"Delphi, a data warehouse to discover associations between variables in clinical trials: application to the fondazione italiana linfomi (FIL) MCL0208 phase III trial","volume":"130","author":"Zaccaria","year":"2017","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/phar.2077","article-title":"Facilitators and barriers to the adoption of pharmacogenetic testing in an inner-city population","volume":"38","author":"Lee","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B95","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12913-017-2205-4","article-title":"Personalized medicine in Europe: not yet personal enough?","volume":"17","author":"Di Paolo","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/ijms18020308","article-title":"Next-generation sequencing in oncology: Genetic diagnosis, risk prediction and cancer classification","volume":"18","author":"Kamps","year":"2017","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01417\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T05:45:04Z","timestamp":1576561504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01417\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":96,"alternative-id":["10.3389\/fonc.2019.01417"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01417","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"article-number":"1417"}}